Vinorelbine Injection, Solution
Product Images NDC 45963-607

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Vinorelbine (NDC 45963-607). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

3c00b60d-figure-01 (Image 1)

Chemical structure of Vinorelbine dihydrogen succinate, showing the molecular arrangement of carbon, hydrogen, nitrogen, and oxygen atoms in the Vinorelbine molecule combined with two succinic acid units.*

FDA Label Image

3c00b60d-figure-02 (Image 2)

A line graph depicting survival rate (%) over time in months after registration, comparing two treatments: IV CDDP and IV CDDP with Vinorelbine. The graph shows survival rate on the vertical axis and months on the horizontal axis, with median survival times and at-risk patient counts noted.*

FDA Label Image

Carton (Image 3)

Vinorelbine Injection, USP 10 mg/mL single-dose vial carton from Teva Pharmaceuticals. The label specifies intravenous use and highlights dilution before use. It includes warnings about cytotoxicity, storage instructions between 2° to 8°C, and notes that the vial stopper is latex-free. The carton displays the NDC 45963-607-55 and manufacturing details from Sindan Pharma SRL in Romania.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.